A Phase 4 interventional study of Vortioxetine and Paroxetine in Healthy Volunteers, sponsored by Takeda. Completed at 15 sites in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-14.
Sponsored by Takeda · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the effect of vortioxetine (10 and 20 mg, once daily) versus paroxetine (20 mg, once daily) on sexual functioning in healthy participants after 5 weeks of double-blind treatment.
The drug being tested in this study is called vortioxetine. This study will look at the effect of treatment on sexual functioning in healthy participants.
The study will enroll approximately 352 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the four treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):
All participants will be asked to take one tablet/capsule, daily, orally for up to 5 weeks.
This multicenter trial will be conducted in United States. The overall time to participate in this study is approximately 7 weeks. Participants will be contacted by telephone 2 weeks after last dose of study drug for a follow-up assessment.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
Drug: Vortioxetine
Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 1 week followed by vortioxetine 20 mg, overencapsulated tablets, orally, once daily from Week 2, up to 4 weeks.
Drug: Vortioxetine
Paroxetine 20 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
Drug: Paroxetine
Vortioxetine placebo matching-capsules, orally, once daily for up to 5 weeks.
Drug: Placebo
Vortioxetine Overencapsulated Tablet
Paroxetine Overencapsulated Tablets.
Vortioxetine Placebo-matching Capsules.
Change From Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Full Analysis Set (FAS)
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.
Time frame: Baseline and Week 5
Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Modified Full Analysis Set 1 (mFAS1)
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.
Time frame: Baseline and Week 5
Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Modified Full Analysis Set 2 (mFAS2)
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.
Time frame: Baseline and Week 5
Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Weeks 1, 2, 3 and 4
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.
Time frame: Baseline and Weeks 1, 2, 3 and 4
Change From Baseline in CSFQ-14 Total Score Difference for Paroxetine Versus Placebo at Weeks 1, 2, 3, 4 and 5
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.
Time frame: Baseline and Weeks 1, 2, 3, 4 and 5
Change From Baseline in CSFQ-14 Total Score Difference for Vortioxetine Versus Placebo at Weeks 1, 2, 3, 4 and 5
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.
Time frame: Baseline and Weeks 1, 2, 3, 4 and 5
Percentage of Participants Meeting Criteria for Sexual Dysfunction at Weeks 1, 2, 3, 4 and 5
Sexual dysfunction is defined as CSFQ-14 score ≤47 for men and ≤41 for women.
Time frame: Weeks 1, 2, 3, 4 and 5
Change From Baseline in CSFQ-14 Subscales 5 Dimensions at Weeks 1, 2, 3, 4 and 5
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning on the subscales of pleasure (1 item, score range 1-5), desire/frequency (2 items, score range 2-10), desire/interest (3 items, score range 3-15), arousal (3 items, score range 3-15), and orgasm (3 items, score range 3-15), rated on a 5-point scale from 1 to 5. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.
Time frame: Baseline and Weeks 1, 2, 3, 4 and 5
Change From Baseline in CSFQ-14 3 Phases of the Sexual Response Cycle (Desire, Arousal, and Orgasm/Completion) at Weeks 1, 2, 3, 4 and 5
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning on the 3 phases of the sexual response cycle , desire (5 items, score range 5-25), arousal (3 items, score range 3-15), and orgasm (3 items, score range 3-15), rated on a 5-point scale from 1 to 5. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.
Time frame: Baseline and Weeks 1, 2, 3, 4 and 5
Participants took part in the study at 16 investigative sites in the United States from 21 November 2016 to 09 June 2017.
| Milestone | Placebo | Paroxetine 20 mg | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|---|
| Started | 92 | 85 | 91 | 93 |
| Treated | 91 | 84 | 91 | 91 |
| Completed | 76 | 67 | 68 | 79 |
| Not completed | 16 | 18 | 23 | 14 |
| Withdrew: Reason not specified | 1 | 0 | 2 | 2 |
| Withdrew: Noncompliance with study drug | 2 | 3 | 3 | 4 |
| Withdrew: Pregnancy | 0 | 1 | 1 | 0 |
| Withdrew: Study termination | 0 | 1 | 0 | 0 |
| Withdrew: Voluntary withdrawal | 2 | 1 | 4 | 2 |
| Withdrew: Lost to follow-up | 5 | 3 | 6 | 0 |
| Withdrew: Significant protocol deviation | 2 | 3 | 6 | 1 |
| Withdrew: Pretreatment event/adverse event | 3 | 5 | 1 | 3 |
| Withdrew: Randomized but not treated | 1 | 1 | 0 | 2 |
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.
| score on a scale | Paroxetine 20 mg | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Baseline | 59.27 ± 0.584 | 58.56 ± 0.578 | 59.43 ± 0.560 |
| Change from Baseline at Week 5 | -3.56 ± 0.758 | -0.82 ± 0.752 | -2.51 ± 0.727 |
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.
| score on a scale | Paroxetine 20 mg | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Week 1 | -1.67 ± 0.457 | -0.54 ± 0.453 | -0.38 ± 0.436 |
| Week 2 | -2.40 ± 0.617 | -1.18 ± 0.612 | -1.55 ± 0.592 |
| Week 3 | -2.77 ± 0.661 | -0.77 ± 0.655 | -2.36 ± 0.633 |
| Week 4 | -3.11 ± 0.688 | -1.20 ± 0.683 | -2.43 ± 0.659 |
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.
| score on a scale | Placebo | Paroxetine 20 mg |
|---|---|---|
| Week 1 | -0.05 ± 0.440 | -1.67 ± 0.457 |
| Week 2 | -1.11 ± 0.598 | -2.40 ± 0.617 |
| Week 3 | -0.91 ± 0.639 | -2.77 ± 0.661 |
| Week 4 | -0.62 ± 0.666 | -3.11 ± 0.688 |
| Week 5 | -0.79 ± 0.734 | -3.56 ± 0.758 |
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.
| score on a scale | Placebo | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Week 1 | -0.05 ± 0.440 | -0.54 ± 0.453 | -0.38 ± 0.436 |
| Week 2 | -1.11 ± 0.598 | -1.18 ± 0.612 | -1.55 ± 0.592 |
| Week 3 | -0.91 ± 0.639 | -0.77 ± 0.655 | -2.36 ± 0.633 |
| Week 4 | -0.62 ± 0.666 | -1.20 ± 0.683 | -2.43 ± 0.659 |
| Week 5 | -0.79 ± 0.734 | -0.82 ± 0.752 | -2.51 ± 0.727 |
Sexual dysfunction is defined as CSFQ-14 score ≤47 for men and ≤41 for women.
| percentage of participants | Placebo | Paroxetine 20 mg | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|---|
| Week 1 | 2.2 | 2.4 | 1.2 | 1.1 |
| Week 2 | 7.9 | 8.4 | 3.5 | 2.2 |
| Week 3 | 4.5 | 8.4 | 3.5 | 6.6 |
| Week 4 | 4.5 | 9.6 | 4.7 | 7.7 |
| Week 5 | 3.4 | 9.6 | 5.9 | 9.9 |
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning on the subscales of pleasure (1 item, score range 1-5), desire/frequency (2 items, score range 2-10), desire/interest (3 items, score range 3-15), arousal (3 items, score range 3-15), and orgasm (3 items, score range 3-15), rated on a 5-point scale from 1 to 5. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.
| score on a scale | Placebo | Paroxetine 20 mg | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|---|
| Pleasure Score: Week 1 | -0.07 ± 0.064 | -0.36 ± 0.066 | -0.13 ± 0.065 | -0.15 ± 0.063 |
| Pleasure Score: Week 2 | -0.26 ± 0.079 | -0.38 ± 0.082 | -0.25 ± 0.081 | -0.26 ± 0.078 |
| Pleasure Score: Week 3 | -0.23 ± 0.085 | -0.44 ± 0.088 | -0.18 ± 0.087 | -0.42 ± 0.084 |
| Pleasure Score: Week 4 | -0.18 ± 0.085 | -0.38 ± 0.088 | -0.31 ± 0.087 | -0.37 ± 0.084 |
| Pleasure Score: Week 5 | -0.21 ± 0.086 | -0.47 ± 0.089 | -0.16 ± 0.088 | -0.33 ± 0.085 |
| Desire/Frequency Score: Week 1 | -0.03 ± 0.097 | -0.35 ± 0.100 | -0.07 ± 0.099 | -0.23 ± 0.096 |
| Desire/Frequency Score: Week 2 | -0.30 ± 0.118 | -0.46 ± 0.122 | -0.25 ± 0.120 | -0.46 ± 0.116 |
| Desire/Frequency Score: Week 3 | -0.33 ± 0.128 | -0.62 ± 0.132 | -0.23 ± 0.131 | -0.50 ± 0.127 |
| Desire/Frequency Score: Week 4 | -0.25 ± 0.126 | -0.55 ± 0.130 | -0.20 ± 0.129 | -0.43 ± 0.125 |
| Desire/Frequency Score: Week 5 | -0.28 ± 0.141 | -0.66 ± 0.145 | -0.15 ± 0.144 | -0.49 ± 0.139 |
| Desire/Interest Score: Week 1 | 0.12 ± 0.162 | -0.15 ± 0.169 | -0.16 ± 0.167 | 0.09 ± 0.161 |
| Desire/Interest Score: Week 2 | -0.09 ± 0.181 | -0.38 ± 0.186 | -0.11 ± 0.185 | -0.22 ± 0.179 |
| Desire/Interest Score: Week 3 | -0.16 ± 0.193 | -0.47 ± 0.200 | -0.01 ± 0.198 | -0.28 ± 0.191 |
| Desire/Interest Score: Week 4 | -0.11 ± 0.200 | -0.52 ± 0.206 | -0.18 ± 0.204 | -0.35 ± 0.198 |
| Desire/Interest Score: Week 5 | -0.14 ± 0.215 | -0.73 ± 0.223 | -0.05 ± 0.221 | -0.33 ± 0.213 |
| Arousal/Excitement/Erection Score: Week 1 | -0.01 ± 0.136 | -0.30 ± 0.141 | -0.05 ± 0.140 | -0.03 ± 0.135 |
| Arousal/Excitement/Erection Score: Week 2 | -0.34 ± 0.175 | -0.47 ± 0.181 | -0.35 ± 0.179 | -0.30 ± 0.174 |
| Arousal/Excitement/Erection Score: Week 3 | -0.22 ± 0.182 | -0.43 ± 0.188 | -0.08 ± 0.186 | -0.51 ± 0.180 |
| Arousal/Excitement/Erection Score: Week 4 | -0.11 ± 0.181 | -0.54 ± 0.187 | -0.10 ± 0.185 | -0.54 ± 0.179 |
| Arousal/Excitement/Erection Score: Week 5 | -0.19 ± 0.195 | -0.67 ± 0.202 | -0.03 ± 0.200 | -0.54 ± 0.193 |
| Orgasm/Completion/Ejaculation Score: Week 1 | -0.12 ± 0.130 | -0.48 ± 0.135 | -0.22 ± 0.134 | -0.15 ± 0.129 |
| Orgasm/Completion/Ejaculation Score: Week 2 | -0.21 ± 0.158 | -0.61 ± 0.164 | -0.26 ± 0.162 | -0.37 ± 0.157 |
| Orgasm/Completion/Ejaculation Score: Week 3 | -0.20 ± 0.176 | -0.75 ± 0.183 | -0.33 ± 0.180 | -0.67 ± 0.175 |
| Orgasm/Completion/Ejaculation Score: Week 4 | -0.14 ± 0.194 | -1.04 ± 0.201 | -0.45 ± 0.199 | -0.72 ± 0.192 |
| Orgasm/Completion/Ejaculation Score: Week 5 | -0.12 ± 0.206 | -1.09 ± 0.214 | -0.42 ± 0.211 | -0.79 ± 0.204 |
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning on the 3 phases of the sexual response cycle , desire (5 items, score range 5-25), arousal (3 items, score range 3-15), and orgasm (3 items, score range 3-15), rated on a 5-point scale from 1 to 5. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.
| score on a scale | Placebo | Paroxetine 20 mg | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|---|
| Desire Score: Week 1 | 0.09 ± 0.225 | -0.50 ± 0.234 | -0.23 ± 0.232 | -0.14 ± 0.223 |
| Desire Score: Week 2 | -0.40 ± 0.260 | -0.83 ± 0.269 | -0.34 ± 0.266 | -0.68 ± 0.258 |
| Desire Score: Week 3 | -0.50 ± 0.286 | -1.09 ± 0.296 | -0.22 ± 0.293 | -0.77 ± 0.284 |
| Desire Score: Week 4 | -0.36 ± 0.297 | -1.07 ± 0.307 | -0.37 ± 0.304 | -0.77 ± 0.294 |
| Desire Score: Week 5 | -0.42 ± 0.325 | -1.38 ± 0.336 | -0.19 ± 0.333 | -0.82 ± 0.322 |
| Arousal Score: Week 1 | -0.01 ± 0.136 | -0.30 ± 0.141 | -0.05 ± 0.140 | -0.03 ± 0.135 |
| Arousal Score: Week 2 | -0.34 ± 0.175 | -0.47 ± 0.181 | -0.35 ± 0.179 | -0.30 ± 0.174 |
| Arousal Score: Week 3 | -0.22 ± 0.182 | -0.43 ± 0.188 | -0.08 ± 0.186 | -0.51 ± 0.180 |
| Arousal Score: Week 4 | -0.11 ± 0.181 | -0.54 ± 0.187 | -0.10 ± 0.185 | -0.54 ± 0.179 |
| Arousal Score: Week 5 | -0.19 ± 0.195 | -0.67 ± 0.202 | -0.03 ± 0.200 | -0.54 ± 0.193 |
| Orgasm/Completion/Ejaculation Score: Week 1 | -0.12 ± 0.130 | -0.48 ± 0.135 | -0.22 ± 0.134 | -0.15 ± 0.129 |
| Orgasm/Completion/Ejaculation Score: Week 2 | -0.21 ± 0.158 | -0.61 ± 0.164 | -0.26 ± 0.162 | -0.37 ± 0.157 |
| Orgasm/Completion/Ejaculation Score: Week 3 | -0.20 ± 0.176 | -0.75 ± 0.183 | -0.33 ± 0.180 | -0.67 ± 0.175 |
| Orgasm/Completion/Ejaculation Score: Week 4 | -0.14 ± 0.194 | -1.04 ± 0.201 | -0.45 ± 0.199 | -0.72 ± 0.192 |
| Orgasm/Completion/Ejaculation Score: Week 5 | -0.12 ± 0.206 | -1.09 ± 0.214 | -0.42 ± 0.211 | -0.79 ± 0.204 |
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.
| score on a scale | Paroxetine 20 mg | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Baseline | 59.13 ± 0.614 | 58.55 ± 0.582 | 59.36 ± 0.576 |
| Change from Baseline at Week 5 | -4.01 ± 0.803 | -0.63 ± 0.763 | -2.38 ± 0.754 |
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70. Higher scores reflect higher sexual functioning. A negative change from baseline indicates that symptoms have worsened.
| score on a scale | Paroxetine 20 mg | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|
| Baseline | 58.73 ± 0.675 | 58.53 ± 0.589 | 59.23 ± 0.591 |
| Change from Baseline at Week 5 | -4.78 ± 0.828 | -0.47 ± 0.724 | -1.72 ± 0.724 |
Collected over From the first dose of study drug on Day 1 until the Follow-up Contact at Week 7. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/91 (0%) | 0/91 (0%) | 36/91 (39.6%) |
| Paroxetine 20 mg | 0/84 (0%) | 0/84 (0%) | 59/84 (70.2%) |
| Vortioxetine 10 mg | 0/91 (0%) | 0/91 (0%) | 52/91 (57.1%) |
| Vortioxetine 20 mg | 0/91 (0%) | 0/91 (0%) | 40/91 (44%) |
| Event | Placebo | Paroxetine 20 mg | Vortioxetine 10 mg | Vortioxetine 20 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 4/91 | 22/84 | 26/91 | 18/91 |
| Libido decreasedPsychiatric disorders | 11/91 | 18/84 | 14/91 | 10/91 |
| Orgasm abnormalPsychiatric disorders | 2/91 | 14/84 | 7/91 | 3/91 |
| SomnolenceNervous system disorders | 4/91 | 10/84 | 7/91 | 7/91 |
| Decreased appetiteMetabolism and nutrition disorders | 1/91 | 6/84 | 4/91 | 1/91 |
| HeadacheNervous system disorders | 6/91 | 6/84 | 2/91 | 6/91 |
| DizzinessNervous system disorders | 1/91 | 6/84 | 0/91 | 1/91 |
| AnxietyPsychiatric disorders | 1/91 | 6/84 | 1/91 | 1/91 |
| InsomniaPsychiatric disorders | 0/91 | 6/84 | 1/91 | 1/91 |
| DiarrhoeaGastrointestinal disorders | 3/91 | 5/84 | 1/91 | 3/91 |
All randomized participants.
| Age, Continuous(years) | Placebo | Paroxetine 20 mg | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|---|
| Mean | 27.8 ± 5.45 | 28.9 ± 5.96 | 28.1 ± 5.56 | 28.8 ± 5.91 | 28.4 ± 5.72 |
| Sex: Female, Male(Participants) | Placebo | Paroxetine 20 mg | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|---|
| Female | 46 | 42 | 44 | 44 | 176 |
| Male | 46 | 43 | 47 | 49 | 185 |
| Race/Ethnicity, Customized(Participants) | Placebo | Paroxetine 20 mg | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 21 | 20 | 25 | 18 | 84 |
| Non-Hispanic and Latino | 71 | 65 | 66 | 75 | 277 |
| Race/Ethnicity, Customized(Participants) | Placebo | Paroxetine 20 mg | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 3 | 0 | 3 |
| Asian | 7 | 3 | 2 | 3 | 15 |
| Black or African American | 30 | 29 | 31 | 34 | 124 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 |
| White | 51 | 49 | 52 | 55 | 207 |
| Multiracial | 4 | 3 | 3 | 1 | 11 |
| Region of Enrollment(Participants) | Placebo | Paroxetine 20 mg | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|---|
| United States | 92 | 85 | 91 | 93 | 361 |
| Median Age Categories(Participants) | Placebo | Paroxetine 20 mg | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|---|
| ≤ 28 Years | 51 | 43 | 52 | 47 | 193 |
| > 28 Years | 41 | 42 | 39 | 46 | 168 |
| Race Categories(Participants) | Placebo | Paroxetine 20 mg | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|---|
| White | 51 | 49 | 52 | 55 | 207 |
| Non-white | 41 | 36 | 39 | 38 | 154 |
| Height(cm) | Placebo | Paroxetine 20 mg | Vortioxetine 10 mg | Vortioxetine 20 mg | Total |
|---|---|---|---|---|---|
| Mean | 172.0 ± 10.75 | 172.1 ± 10.59 | 171.3 ± 9.14 | 170.8 ± 10.04 | 171.5 ± 10.12 |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in May 2017, 6 months.
Results were first posted in Sep 2018, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine